Overview: Drug manufacturers, insurers and other stakeholders are crying out for this antiquated system to be brought into modernity – even if it is kicking and screaming all the way.
Stakeholders are demanding that drug pricing move from a volume to value based system so as to properly allocate research and healthcare dollars. They are looking to share the risk of these endeavors through value based contracting, but are met with legal and regulatory obstacles, namely the fraud and abuse and anti-kickback laws.
View conference bios here.
Top Healthcare and Pharmaceutical Trends in 2017 – Webinar
Partner webinar from AMI. Overview: The year 2016 saw a “pause” in most market trends as the U.S. Presidential election cycle unfolded and BREXIT occurred. As we begin 2017 with a new republican leadership in Washington, D.C. led by outsider and now President Donald Trump, we know change will happen going forward throughout all segments of the U.S. market.
How will these new policy leaders impact the landscape and in which ways might that alter efforts for your organization can be gleaned from top-line insights on the market landscape. Learn more about Access Market Intelligence here.